| P2093 | author name string | Marcel G M Olde Rikkert | |
| | Marcel M Verbeek | |
| | Berry P H Kremer | |
| | Daniëlle de Jong | |
| P2860 | cites work | Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis | Q21144689 |
| | Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis | Q24678722 |
| | Neuropathological stageing of Alzheimer-related changes | Q27860862 |
| | Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease | Q28220675 |
| | Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies. | Q53275812 |
| | CSF BACE1 activity is increased in CJD and Alzheimer disease versus [corrected] other dementias. | Q53280434 |
| | ACE activity in CSF of patients with mild cognitive impairment and Alzheimer disease. | Q53281698 |
| | Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. | Q53285087 |
| | Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins. | Q53285844 |
| | Longitudinal stability of CSF biomarkers in Alzheimer's disease. | Q53286684 |
| | Cerebrospinal fluid tau levels in frontotemporal dementia. | Q53373930 |
| | Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. | Q53380130 |
| | Tau missing from CSF: a case report. | Q53500635 |
| | Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF | Q55952248 |
| | S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease | Q57274052 |
| | CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment | Q57675704 |
| | Effect of Sample Collection Tubes on Cerebrospinal Fluid Concentrations of Tau Proteins and Amyloid Peptides | Q57780700 |
| | Tau Protein in Cerebrospinal Fluid | Q58006801 |
| | Cerebrospinal protein tau is elevated in early Alzheimer's disease. | Q53213849 |
| | No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia. | Q53225650 |
| | Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. | Q53245453 |
| | Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. | Q53246695 |
| | Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group. | Q53247832 |
| | International quality control survey of neurochemical dementia diagnostics. | Q53248206 |
| | Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? | Q53259076 |
| | Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. | Q53270013 |
| | Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21 | Q28253639 |
| | Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17 | Q28253651 |
| | Towards a high resolution separation of human cerebrospinal fluid. | Q30708834 |
| | Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology | Q30822398 |
| | Analysis of the human lumbar cerebrospinal fluid proteome | Q30834718 |
| | A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. | Q30977031 |
| | Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. | Q31078434 |
| | Identification of proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing as a prefractionation step followed by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionisation mass spectrometry | Q31117598 |
| | The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide | Q33187435 |
| | Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease | Q33199637 |
| | Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. | Q33223096 |
| | Proteome studies of CSF in AD patients. | Q33227405 |
| | Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis | Q33232505 |
| | Identification of potential CSF biomarkers in ALS. | Q33234070 |
| | Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects | Q33237201 |
| | CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia | Q33239180 |
| | An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid | Q33260793 |
| | Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease | Q33850134 |
| | Evidence based diagnostics | Q33934950 |
| | Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study | Q34287865 |
| | Neurofilament protein synthesis and phosphorylation | Q34315422 |
| | Proteome-based plasma biomarkers for Alzheimer's disease | Q34577503 |
| | Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid | Q34636479 |
| | Lipid peroxidation in aging brain and Alzheimer's disease | Q34809194 |
| | Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases | Q35051036 |
| | Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease | Q35114490 |
| | Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers | Q35134373 |
| | Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia | Q35450021 |
| | Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease? | Q35463972 |
| | CSF markers for incipient Alzheimer's disease | Q35541472 |
| | Cerebrospinal fluid protein biomarkers for Alzheimer's disease | Q36045282 |
| | Comparative accuracy: assessing new tests against existing diagnostic pathways | Q36468809 |
| | Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type | Q36880979 |
| | Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults | Q40253365 |
| | Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study | Q40349700 |
| | Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay | Q40404080 |
| | Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease | Q40592316 |
| | Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau | Q42049071 |
| | The Topographical and Neuroanatomical Distribution of Neurofibrillary Tangles and Neuritic Plaques in the Cerebral Cortex of Patients with Alzheimer's Disease | Q42470207 |
| | Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study | Q42912092 |
| | Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease | Q43708035 |
| | Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease | Q43747318 |
| | Pathophysiological aspects of frontotemporal dementia--emphasis on cytoskeleton proteins and autoimmunity. | Q43758855 |
| | Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. | Q44091581 |
| | High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. | Q45192211 |
| | Plasma amyloid beta protein 42 in non-demented persons aged 75 years: effects of concomitant medication and medial temporal lobe atrophy | Q46510354 |
| | Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease | Q46812249 |
| | CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival | Q46878198 |
| | The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease | Q46949879 |
| | Elevated interleukin-6 levels in cerebrospinal fluid of vascular dementia patients | Q47227623 |
| | Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease | Q47692868 |
| | Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy | Q47852588 |
| | Haplotypes extending across ACE are associated with Alzheimer's disease | Q48001501 |
| | Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias | Q48010180 |
| | Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease | Q48172055 |
| | Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease | Q48198034 |
| | Plasma Abeta levels do not reflect brain Abeta levels | Q48214768 |
| | Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease | Q48266934 |
| | Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. | Q48280212 |
| | Soluble adhesion molecules and angiotensin-converting enzyme in dementia | Q48290054 |
| | High levels of nervous system-specific proteins in cerebrospinal fluid in patients with early stage Creutzfeldt-Jakob disease | Q48419470 |
| | Accuracy of clinical operational diagnostic criteria for Alzheimer's disease in relation to different pathological diagnostic protocols | Q48422285 |
| | CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. | Q48494001 |
| | The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease | Q48536651 |
| | Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels | Q48555754 |
| | Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease | Q48584697 |
| | CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. | Q48613157 |
| | Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients | Q48684554 |
| | Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease | Q48891427 |
| | The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies | Q48913771 |
| | Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease | Q48913788 |
| | Different variants of frontotemporal dementia: a neuropathological and immunohistochemical study | Q48952411 |
| | Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies | Q49168413 |
| | Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. | Q50959210 |
| | Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. | Q51094071 |
| | Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. | Q51576488 |
| | Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. | Q51762261 |
| | Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. | Q51914558 |
| | Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. | Q51983988 |
| | Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. | Q51984405 |
| | Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination. | Q51993128 |
| | CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. | Q52057738 |
| | Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. | Q53200382 |
| | Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? | Q53212854 |
| P433 | issue | 11 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| | biomarker | Q864574 |
| P304 | page(s) | 1421-1434 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Clinical Chemistry and Laboratory Medicine | Q5133754 |
| P1476 | title | Current state and future directions of neurochemical biomarkers for Alzheimer's disease | |
| P478 | volume | 45 | |